GSK has reached ... 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has agreed to pay $2.2 billion to settle ...

GSK plc (NYSE:GSK) – GSK agreed to pay up to $2.2 billion to settle 93% of U.S. lawsuits related to Zantac, alleging the drug caused cancer. The settlement, announced Wednesday, was lower than ...

GSK last month agreed to settle about 80,000 Zantac lawsuits, representing most of the litigation against it, for $2.2 billion. Pfizer has also agreed to settle most of the outstanding cases ...

This writer takes a look at a beaten down FTSE 100 stock that has been sliding lower. Has it reached his Buy zone yet or is it one to watch? The post Why this falling FTSE 100 stock could be entering ...

The three-day hearing comes a few months after GSK decided to settle a complaint brought ... The common claim in the lawsuits is that a contaminant in Zantac (ranitidine) called N ...

Consulting firm has agreed to pay $650 million to settle a federal investigation into its work for opioids manufacturer ...

A former top partner at McKinsey also agreed to plead guilty to obstruction of justice in the probe, according to court ...

McKinsey & Company consulting firm has agreed to pay $650 million to settle a federal investigation into its work for opioids ...

Walt Disney Co. has agreed ... long-running lawsuit brought by a group of female employees who alleged gender pay discrimination at the Burbank entertainment giant. The proposed settlement was ...